Cytrx Cp (CYTR) 2.30 $CYTR
Biotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx
PR Newswire - Fri Jun 17, 7:50AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and CytRx Corporation (NASDAQ: CYTR). Learn more about these stocks by accessing their free trade alerts at:
MACK: 6.00 (-0.12), ALNY: 54.85 (-2.10), GERN: 2.65 (-0.10), CYTR: 2.30 (-0.09)
CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical Oncology Annual Meeting
PR Newswire - Mon Jun 06, 8:00AM CDT
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the presentation of three posters featuring updated clinical data from its aldoxorubicin clinical trials at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2016, at McCormick Place in Chicago.
CYTR: 2.30 (-0.09)
CytRx to Present at Jefferies 2016 Global Healthcare Conference
PR Newswire - Tue May 31, 8:00AM CDT
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Olivia Ware, Chief Commercial Officer, and David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at the Jefferies 2016 Global Healthcare Conference on Tuesday, June 7th at 4:30 p.m. Eastern Time in New York City.
CYTR: 2.30 (-0.09)
CytRx Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 11, 8:00AM CDT
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended March 31, 2016, and provided an overview of recent accomplishments and upcoming milestones for its research and development programs.
CYTR: 2.30 (-0.09)
CytRx to Present at Joseph Gunnar and Co.'s PIONEERS 2016 Investor Conference
PR Newswire - Thu Apr 28, 8:00AM CDT
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at the Joseph Gunnar and Co. PIONEERS 2016 Investor Conference on Thursday, May 5th at 11:30 a.m. Eastern Time. The conference will take place at the New York Palace Hotel in New York City.
CYTR: 2.30 (-0.09)
CytRx and PRA Health Sciences Receive Gold Awards for Excellence in Clinical Research as the Strategic Partnership Team of the Year
PR Newswire - Mon Apr 25, 8:00AM CDT
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that two members of its clinical development team, Scott Wieland, Ph.D., Senior Vice President, Drug Development, and Nancy Wu, Senior Director of Clinical Operations, received the prestigious gold award at the PharmaTimes Clinical Researcher of the Year - The Americas competition held in Atlanta, Georgia. The award in the Strategic Partnership Team category is shared with CytRx's partners at PRA Health Sciences, Inc., (PRA) (Nasdaq: PRAH), which was also recognized at the competition as the Best Clinical Research Company of the Year for the second consecutive year.
CYTR: 2.30 (-0.09), PRAH: 42.61 (-1.28)
CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016
PR Newswire - Wed Apr 20, 8:00AM CDT
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that three aldoxorubicin clinical trials have been accepted for poster presentations during the American Society of Clinical Oncology (ASCO) Annual Meeting being held at McCormick Place in Chicago, Illinois, from June, 3-7, 2016. The three clinical trials to be presented are:
CYTR: 2.30 (-0.09)
CytRx Corp (CYTR) in Focus: Stock Rises 10.2% in Session
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 7:15AM CDT
CytRx Corporation (CYTR) shares rose over 10% in the last trading session.
CYTR: 2.30 (-0.09), ANIK: 50.30 (-0.80)
CytRx to Present New Data Using Its Proprietary LADR(TM) Technology at the 2016 American Association for Cancer Research Annual Meeting
PR Newswire - Tue Mar 22, 8:00AM CDT
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will present two posters with new preclinical data based on its proprietary LADR(TM) technology at the upcoming 2016 American Association of Cancer Research (AACR) Annual Meeting, April 16-20, 2016, being held at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
CYTR: 2.30 (-0.09)
CytRx Reports 2015 Financial Results
PR Newswire - Fri Mar 11, 8:00AM CST
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the year ended December 31, 2015, and provided an overview of recent accomplishments and upcoming milestones for its research and development programs.
CYTR: 2.30 (-0.09)
Kahn Swick & Foti, LLC Announces Proposed Settlement of CytRx Corporation Securities Litigation
PR Newswire - Fri Feb 19, 10:30AM CST
The following statement is being issued by Kahn Swick & Foti, LLC regarding the CytRx Corporation Securities Litigation:
CYTR: 2.30 (-0.09)
Non-Small Cell Lung Cancer - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnx7gl/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Non-Small Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Non-Small Cell Lung Cancer - Overview - Pipeline Products for Non-Small Cell Lung Cancer - Comparative Analysis - Non-Small Cell Lung Cancer - Therapeutics under Development by Companies - Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Non-Small Cell Lung Cancer - Products under Development by Companies - Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - Arch Biopartners, Inc. - Ariad Pharmaceuticals, Inc. - Arog Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Axelar AB - CTI BioPharma Corp. - CureFAKtor Pharmaceuticals, LLC - CureVac GmbH - CytRx Corporation - Daiichi Sankyo Company, Limited - DanDrit Biotech A/S - Viralytics Ltd. - XBiotech USA, Inc. - Zhejiang BetaPharma Co., Ltd. - Zyngenia, Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/pn...small_cell
AZN: 28.38 (-0.91), ACH: 7.59 (-0.28), CYTR: 2.30 (-0.09), AVEO: 0.95 (-0.03), ARQL: 1.84 (-0.08), CTIC: 0.36 (-0.04), ARRY: 3.48 (-0.10)
Global Soft Tissue Sarcoma Therapeutics Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/thz6jx/soft_tissue) has announced the addition of the "Soft Tissue Sarcoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Soft Tissue Sarcoma Overview - Therapeutics Development - Pipeline Products for Soft Tissue Sarcoma - Overview - Pipeline Products for Soft Tissue Sarcoma - Comparative Analysis - Soft Tissue Sarcoma - Therapeutics under Development by Companies - Soft Tissue Sarcoma - Therapeutics under Investigation by Universities/Institutes - Soft Tissue Sarcoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Soft Tissue Sarcoma - Products under Development by Companies - Soft Tissue Sarcoma - Products under Investigation by Universities/Institutes - Soft Tissue Sarcoma - Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Amgen Inc. - Arog Pharmaceuticals, Inc. - Bayer AG - CASI Pharmaceuticals Inc. - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Cellectar Biosciences, Inc. - CytRx Corporation - Daiichi Sankyo Company, Limited - Double Bond Pharmaceutical International AB - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Gem Pharmaceuticals, LLC - GlaxoSmithKline Plc - Lytix Biopharma AS - MedImmune, LLC - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Noxxon Pharma AG - OncoTherapy Science, Inc. - Onxeo SA - Pfizer Inc. - Pharma Mar, S.A. - Philogen S.p.A. - Plexxikon Inc. - Siena Biotech S.p.A. - Sigma-Tau S.p.A. - Sumitomo Dainippon Pharma Co., Ltd. - Targovax AS For more information visit http://www.researchandmarkets.com/research/th...oft_tissue
CLRB: 3.40 (-0.10), PFE: 34.31 (-0.28), AMGN: 148.57 (-3.70), LLY: 74.36 (+0.42), EPZM: 9.82 (-0.62), GSK: 41.39 (-1.17), CASI: 1.22 (-0.01), MACK: 6.00 (-0.12), MRK: 56.85 (-0.83), CYTR: 2.30 (-0.09), NVS: 78.81 (-1.86), CELGZ: 1.54 (+0.09), EXEL: 7.72 (-0.13)
CytRx to Present at the 18th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 01, 8:00AM CST
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at the 18th Annual BIO CEO & Investor Conference on Monday, February 8th at 11:00 a.m. Eastern Time. CytRx expects to announce top-line data in the second quarter from its global pivotal Phase 3 clinical trial of aldoxorubicin in second-line soft tissue sarcomas which is being conducted under a Special Protocol Assessment from the FDA. The conference will take place at the Waldorf Astoria Hotel in New York City.
CYTR: 2.30 (-0.09)
Metastatic Pancreatic Cancer - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/28xgl2/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Metastatic Pancreatic Cancer Overview - Therapeutics Development - Pipeline Products for Metastatic Pancreatic Cancer - Overview - Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis - Metastatic Pancreatic Cancer - Therapeutics under Development by Companies - Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes - Metastatic Pancreatic Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Metastatic Pancreatic Cancer - Products under Development by Companies - Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes - Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - AbbVie Inc. - Aduro BioTech, Inc. - ArQule, Inc. - Array BioPharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Axcentua Pharmaceuticals AB - Biothera, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Cantex Pharmaceuticals, Inc. - Celgene Corporation - Clovis Oncology, Inc. - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - CytRx Corporation - Eleison Pharmaceuticals, Inc. - Eli Lilly and Company - Ensol Biosciences Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Fountain Biopharma Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - (30 Others) For more information visit http://www.researchandmarkets.com/research/28xgl2/metastatic
ADRO: 10.30 (-0.63), ARQL: 1.84 (-0.08), LLY: 74.36 (+0.42), GSK: 41.39 (-1.17), BMY: 71.53 (-1.11), CTIC: 0.36 (-0.04), GILD: 81.88 (-1.49), CLVS: 13.34 (-0.59), AZN: 28.38 (-0.91), AVEO: 0.95 (-0.03), CYTR: 2.30 (-0.09), ABBV: 60.38 (-0.93), ARRY: 3.48 (-0.10), CELGZ: 1.54 (+0.09)
New Strong Buy Stocks for January 14th
Zacks Equity Research - Zacks Investment Research - Thu Jan 14, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
COT: 14.77 (-0.52), AZPN: 39.10 (-1.21), LOGM: 63.33 (-2.41), CYTR: 2.30 (-0.09), CELG: 97.92 (-2.74)
Biotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx
PR Newswire - Fri Jun 17, 7:50AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and CytRx Corporation (NASDAQ: CYTR). Learn more about these stocks by accessing their free trade alerts at:
MACK: 6.00 (-0.12), ALNY: 54.85 (-2.10), GERN: 2.65 (-0.10), CYTR: 2.30 (-0.09)
CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical Oncology Annual Meeting
PR Newswire - Mon Jun 06, 8:00AM CDT
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the presentation of three posters featuring updated clinical data from its aldoxorubicin clinical trials at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2016, at McCormick Place in Chicago.
CYTR: 2.30 (-0.09)
CytRx to Present at Jefferies 2016 Global Healthcare Conference
PR Newswire - Tue May 31, 8:00AM CDT
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Olivia Ware, Chief Commercial Officer, and David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at the Jefferies 2016 Global Healthcare Conference on Tuesday, June 7th at 4:30 p.m. Eastern Time in New York City.
CYTR: 2.30 (-0.09)
CytRx Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 11, 8:00AM CDT
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended March 31, 2016, and provided an overview of recent accomplishments and upcoming milestones for its research and development programs.
CYTR: 2.30 (-0.09)
CytRx to Present at Joseph Gunnar and Co.'s PIONEERS 2016 Investor Conference
PR Newswire - Thu Apr 28, 8:00AM CDT
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at the Joseph Gunnar and Co. PIONEERS 2016 Investor Conference on Thursday, May 5th at 11:30 a.m. Eastern Time. The conference will take place at the New York Palace Hotel in New York City.
CYTR: 2.30 (-0.09)
CytRx and PRA Health Sciences Receive Gold Awards for Excellence in Clinical Research as the Strategic Partnership Team of the Year
PR Newswire - Mon Apr 25, 8:00AM CDT
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that two members of its clinical development team, Scott Wieland, Ph.D., Senior Vice President, Drug Development, and Nancy Wu, Senior Director of Clinical Operations, received the prestigious gold award at the PharmaTimes Clinical Researcher of the Year - The Americas competition held in Atlanta, Georgia. The award in the Strategic Partnership Team category is shared with CytRx's partners at PRA Health Sciences, Inc., (PRA) (Nasdaq: PRAH), which was also recognized at the competition as the Best Clinical Research Company of the Year for the second consecutive year.
CYTR: 2.30 (-0.09), PRAH: 42.61 (-1.28)
CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016
PR Newswire - Wed Apr 20, 8:00AM CDT
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that three aldoxorubicin clinical trials have been accepted for poster presentations during the American Society of Clinical Oncology (ASCO) Annual Meeting being held at McCormick Place in Chicago, Illinois, from June, 3-7, 2016. The three clinical trials to be presented are:
CYTR: 2.30 (-0.09)
CytRx Corp (CYTR) in Focus: Stock Rises 10.2% in Session
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 7:15AM CDT
CytRx Corporation (CYTR) shares rose over 10% in the last trading session.
CYTR: 2.30 (-0.09), ANIK: 50.30 (-0.80)
CytRx to Present New Data Using Its Proprietary LADR(TM) Technology at the 2016 American Association for Cancer Research Annual Meeting
PR Newswire - Tue Mar 22, 8:00AM CDT
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will present two posters with new preclinical data based on its proprietary LADR(TM) technology at the upcoming 2016 American Association of Cancer Research (AACR) Annual Meeting, April 16-20, 2016, being held at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
CYTR: 2.30 (-0.09)
CytRx Reports 2015 Financial Results
PR Newswire - Fri Mar 11, 8:00AM CST
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the year ended December 31, 2015, and provided an overview of recent accomplishments and upcoming milestones for its research and development programs.
CYTR: 2.30 (-0.09)
Kahn Swick & Foti, LLC Announces Proposed Settlement of CytRx Corporation Securities Litigation
PR Newswire - Fri Feb 19, 10:30AM CST
The following statement is being issued by Kahn Swick & Foti, LLC regarding the CytRx Corporation Securities Litigation:
CYTR: 2.30 (-0.09)
Non-Small Cell Lung Cancer - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnx7gl/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Non-Small Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Non-Small Cell Lung Cancer - Overview - Pipeline Products for Non-Small Cell Lung Cancer - Comparative Analysis - Non-Small Cell Lung Cancer - Therapeutics under Development by Companies - Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Non-Small Cell Lung Cancer - Products under Development by Companies - Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - Arch Biopartners, Inc. - Ariad Pharmaceuticals, Inc. - Arog Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Axelar AB - CTI BioPharma Corp. - CureFAKtor Pharmaceuticals, LLC - CureVac GmbH - CytRx Corporation - Daiichi Sankyo Company, Limited - DanDrit Biotech A/S - Viralytics Ltd. - XBiotech USA, Inc. - Zhejiang BetaPharma Co., Ltd. - Zyngenia, Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/pn...small_cell
AZN: 28.38 (-0.91), ACH: 7.59 (-0.28), CYTR: 2.30 (-0.09), AVEO: 0.95 (-0.03), ARQL: 1.84 (-0.08), CTIC: 0.36 (-0.04), ARRY: 3.48 (-0.10)
Global Soft Tissue Sarcoma Therapeutics Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/thz6jx/soft_tissue) has announced the addition of the "Soft Tissue Sarcoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Soft Tissue Sarcoma Overview - Therapeutics Development - Pipeline Products for Soft Tissue Sarcoma - Overview - Pipeline Products for Soft Tissue Sarcoma - Comparative Analysis - Soft Tissue Sarcoma - Therapeutics under Development by Companies - Soft Tissue Sarcoma - Therapeutics under Investigation by Universities/Institutes - Soft Tissue Sarcoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Soft Tissue Sarcoma - Products under Development by Companies - Soft Tissue Sarcoma - Products under Investigation by Universities/Institutes - Soft Tissue Sarcoma - Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Amgen Inc. - Arog Pharmaceuticals, Inc. - Bayer AG - CASI Pharmaceuticals Inc. - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Cellectar Biosciences, Inc. - CytRx Corporation - Daiichi Sankyo Company, Limited - Double Bond Pharmaceutical International AB - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Gem Pharmaceuticals, LLC - GlaxoSmithKline Plc - Lytix Biopharma AS - MedImmune, LLC - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Noxxon Pharma AG - OncoTherapy Science, Inc. - Onxeo SA - Pfizer Inc. - Pharma Mar, S.A. - Philogen S.p.A. - Plexxikon Inc. - Siena Biotech S.p.A. - Sigma-Tau S.p.A. - Sumitomo Dainippon Pharma Co., Ltd. - Targovax AS For more information visit http://www.researchandmarkets.com/research/th...oft_tissue
CLRB: 3.40 (-0.10), PFE: 34.31 (-0.28), AMGN: 148.57 (-3.70), LLY: 74.36 (+0.42), EPZM: 9.82 (-0.62), GSK: 41.39 (-1.17), CASI: 1.22 (-0.01), MACK: 6.00 (-0.12), MRK: 56.85 (-0.83), CYTR: 2.30 (-0.09), NVS: 78.81 (-1.86), CELGZ: 1.54 (+0.09), EXEL: 7.72 (-0.13)
CytRx to Present at the 18th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 01, 8:00AM CST
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at the 18th Annual BIO CEO & Investor Conference on Monday, February 8th at 11:00 a.m. Eastern Time. CytRx expects to announce top-line data in the second quarter from its global pivotal Phase 3 clinical trial of aldoxorubicin in second-line soft tissue sarcomas which is being conducted under a Special Protocol Assessment from the FDA. The conference will take place at the Waldorf Astoria Hotel in New York City.
CYTR: 2.30 (-0.09)
Metastatic Pancreatic Cancer - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/28xgl2/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Metastatic Pancreatic Cancer Overview - Therapeutics Development - Pipeline Products for Metastatic Pancreatic Cancer - Overview - Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis - Metastatic Pancreatic Cancer - Therapeutics under Development by Companies - Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes - Metastatic Pancreatic Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Metastatic Pancreatic Cancer - Products under Development by Companies - Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes - Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - AbbVie Inc. - Aduro BioTech, Inc. - ArQule, Inc. - Array BioPharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Axcentua Pharmaceuticals AB - Biothera, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Cantex Pharmaceuticals, Inc. - Celgene Corporation - Clovis Oncology, Inc. - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - CytRx Corporation - Eleison Pharmaceuticals, Inc. - Eli Lilly and Company - Ensol Biosciences Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Fountain Biopharma Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - (30 Others) For more information visit http://www.researchandmarkets.com/research/28xgl2/metastatic
ADRO: 10.30 (-0.63), ARQL: 1.84 (-0.08), LLY: 74.36 (+0.42), GSK: 41.39 (-1.17), BMY: 71.53 (-1.11), CTIC: 0.36 (-0.04), GILD: 81.88 (-1.49), CLVS: 13.34 (-0.59), AZN: 28.38 (-0.91), AVEO: 0.95 (-0.03), CYTR: 2.30 (-0.09), ABBV: 60.38 (-0.93), ARRY: 3.48 (-0.10), CELGZ: 1.54 (+0.09)
New Strong Buy Stocks for January 14th
Zacks Equity Research - Zacks Investment Research - Thu Jan 14, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
COT: 14.77 (-0.52), AZPN: 39.10 (-1.21), LOGM: 63.33 (-2.41), CYTR: 2.30 (-0.09), CELG: 97.92 (-2.74)
